| Ytd | 23.72% | |
| 1y | 7.22% |
| Open | 10.15 | Prev Close | 10.00 | Low | 9.59 | High | 10.15 | Mkt Cap | 2.45B |
| Vol | 4.83M | Avg Vol | 4.99M | EPS | -1.77 | P/E | N/A | Forward P/E | 14.19 |
| Beta | 0.56 | Short Ratio | 10.68 | Inst. Own | 101.14% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 8.94 | 200-d Avg | 8.00 | 1yr Est | 21.30 |
HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy
Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Cana
Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overwei
BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ("BioCryst" or the "Company") today ann
—Advances strategic shift toward a disciplined research model prioritizing external innovation to ac
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven ab
Studies highlight the significant healthcare and quality-of-life burden associated with hereditary a
BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and rec
Citizens analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperfo
Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers
Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the
BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to
BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.14 per share which beat the analyst
— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibar
PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global
BioCryst Pharma (NASDAQ:BCRX) affirms FY2026 sales outlook from $635.000 million-$660.000 million to
BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.06 per share which beat the analyst
BioCryst Pharma (NASDAQ:BCRX) reported quarterly sales of $163.284 million which beat the analyst co
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present nine abs
RBC Capital analyst Brian Abrahams maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and
BioCryst Pharma (NASDAQ:BCRX) sees FY2026 sales of $635.000 million-$660.000 million vs $657.200 mil
HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy
BioCryst secures FDA approval for Orladeyo oral pellets, expanding preventive HAE therapy to childre
–ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and old
Findings highlight negative psychosocial impact of HAE attacks and resulting ED/hospital visits on
Citizens analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperfo
Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:BCRX) with a Equal-Weight and lowers
Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and lowers the
Retail investors are preparing for another busy week of earnings season with more than 1,600 compani
BioCryst Pharma (NASDAQ:BCRX) raises FY2025 sales outlook from $580.000 million-$600.000 million to
BioCryst Pharma (NASDAQ:BCRX) reported quarterly earnings of $0.16 per share which beat the analyst
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abs
Cantor Fitzgerald analyst Steven Seedhouse maintains BioCryst Pharma (NASDAQ:BCRX) with a Overwei
JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Ou
Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and raises the
BioCryst will acquire Astria Therapeutics for $700 million to expand its HAE portfolio with naveniba
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and s